Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs

Astrid A M Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P de Boer, Henri N J M Greuter, N Harry Hendrikse, Jonas Eriksson, Albert D Windhorst, Pieter E Postmus, Henk M Verheul, Erik H Serné, Adriaan A Lammertsma, Egbert F Smit

Research output: Contribution to journalArticleAcademicpeer-review

281 Citations (Scopus)

Abstract

Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.

Original languageEnglish
Pages (from-to)82-91
Number of pages10
JournalCancer Cell
Volume21
Issue number1
DOIs
Publication statusPublished - 17 Jan 2012
Externally publishedYes

Bibliographical note

Copyright © 2012 Elsevier Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs'. Together they form a unique fingerprint.

Cite this